Table 4 Characteristics’ of patients with germline BRCA mutation treated with PARP inhibitor monotherapy

From: A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit

Patient

26

28

35

66

67

TTP (months)

7

5

5

3

7a

Best response

SD

SD

SD

SD

PR

ER status

Negative

Positive

Negative

Positive

Negative

PR status

Negative

Negative

Negative

Negative

Negative

HER2 status

Negative

Negative

Negative

Negative

Negative

BRCA status

BRCA1

BRCA2

BRCA2

BRCA2

BRCA2

Pathology

IDC

IDC

IDC

IDC

IDC

Lines chemo MTX

4

2

1

2

1

Time MTX to phase I

22 months

16 months

20 months

27 months

12 months

  1. Abbreviations: ER=oestrogen receptor; HER2=epidermal growth factor receptor 2; IDC=invasive ductal carcinoma; MTX=metastatic disease; PARP=Poly (ADP-ribose) polymerase; PR=progesterone receptor; TTP=time to progression.
  2. aOngoing PR at radiological 7-month assessment.
  3. Partial response (PR) and stable disease (SD) according to response evaluation criteria in solid tumours (RECIST).
Back to article page